新股消息 | 迪哲医药(688192.SH)二次递表港交所

智通财经06:22

【新股消息 | 迪哲医药(688192.SH)二次递表港交所】智通财经APP获悉，据港交所8月27日披露，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))向港交所主板递交上市申请书，高盛和华泰国际为其联席保荐人。该公司曾于1月23日向港交所递交上市申请。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。于往绩记录期间，迪哲医药在中国内地开发并商业化戈利昔替尼(高瑞哲®)，一种新一代高选择性Janus激酶1(“JAK1”)抑制剂。此外，迪哲医药开发、商业化并对外授权舒沃哲®，它是全球范围内首款获批用于治疗EGFR 20号外显子插入(“exon20ins”)突变型肺癌的小分子表皮生长因子受体(“EGFR”)酪氨酸激酶抑制剂(“TKI”)。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2662393220?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-28 06:22","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2662393220","market":"hk","top_or_hot":-1,"title":"新股消息 | 迪哲医药(688192.SH)二次递表港交所","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【新股消息 | 迪哲医药(688192.SH)二次递表港交所】</b>智通财经APP获悉，据港交所8月27日披露，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))向港交所主板递交上市申请书，高盛和华泰国际为其联席保荐人。该公司曾于1月23日向港交所递交上市申请。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。于往绩记录期间，迪哲医药在中国内地开发并商业化戈利昔替尼(高瑞哲®)，一种新一代高选择性Janus激酶1(“JAK1”)抑制剂。此外，迪哲医药开发、商业化并对外授权舒沃哲®，它是全球范围内首款获批用于治疗EGFR \n\n20号外显子插入(“exon20ins”)突变型肺癌的小分子表皮生长因子受体(“EGFR”)酪氨酸激酶抑制剂(“TKI”)。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股消息 | 迪哲医药(688192.SH)二次递表港交所</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股消息 | 迪哲医药(688192.SH)二次递表港交所\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【新股消息 | 迪哲医药(688192.SH)二次递表港交所】</b>智通财经APP获悉，据港交所8月27日披露，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))向港交所主板递交上市申请书，高盛和华泰国际为其联席保荐人。该公司曾于1月23日向港交所递交上市申请。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。于往绩记录期间，迪哲医药在中国内地开发并商业化戈利昔替尼(高瑞哲®)，一种新一代高选择性Janus激酶1(“JAK1”)抑制剂。此外，迪哲医药开发、商业化并对外授权舒沃哲®，它是全球范围内首款获批用于治疗EGFR \n\n20号外显子插入(“exon20ins”)突变型肺癌的小分子表皮生长因子受体(“EGFR”)酪氨酸激酶抑制剂(“TKI”)。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2662393220","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662393220","pubTimestamp":1787869340,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【新股消息 | 迪哲医药(688192.SH)二次递表港交所】智通财经APP获悉，据港交所8月27日披露，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))向港交所主板递交上市申请书","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1574":"生物医药B类股","BK1161":"生物科技","09939":"开拓药业-B"},"translate_title":"IPO News | Dizhe Pharmaceutical (688192.SH) Submits Second Listing to the Hong Kong Stock Exchange","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1.5},"content_text":"【新股消息 | 迪哲医药(688192.SH)二次递表港交所】智通财经APP获悉，据港交所8月27日披露，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))向港交所主板递交上市申请书，高盛和华泰国际为其联席保荐人。该公司曾于1月23日向港交所递交上市申请。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。于往绩记录期间，迪哲医药在中国内地开发并商业化戈利昔替尼(高瑞哲®)，一种新一代高选择性Janus激酶1(“JAK1”)抑制剂。此外，迪哲医药开发、商业化并对外授权舒沃哲®，它是全球范围内首款获批用于治疗EGFR \n\n20号外显子插入(“exon20ins”)突变型肺癌的小分子表皮生长因子受体(“EGFR”)酪氨酸激酶抑制剂(“TKI”)。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2662393220","isCrawlerRequest":true}